

TACROLIMUS TOPICAL OINTMENT SPECIAL AUTHORIZATION REQUEST FORM

Please complete all required sections to allow your request to be processed.

Patients may or may not meet eligibility requirements as established by Alberta Government sponsored drug programs.

processea.				Albeita	Government sponsored drug programs.
PATIENT INFORMATION					COVERAGE TYPE:
PATIENT LAST NAME	FIRST NAME	•		INITIAL	☐ Alberta Blue Cross ☐ Alberta Human Services
DATE OF BIRTH: Year / Month / Day	ALBERTA PERSONAL HEALTH NUMBER			₹	Other
STREET ADDRESS	CIT	Υ	PROV	POSTAL CODE	IDENTIFICATION/CLIENT/COVERAGE No:
PRESCRIBER INFORMATION					
PRESCRIBER LAST NAME FIRST NAME INITIAL			PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION		
			☐ CPSA ☐ ACO REGISTRATION NO.		
STREET ADDRESS			☐ CARNA ☐ ACP	☐ ADA+C ☐ Other	
CITY DDOVING			PHONE:		FAX:
CITY , PROVINCE					
POSTAL CODE			FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED		
Please provide the following information for ALL requests:					
Indicate which drug is requested (check ONE box): Tacrolimus 0.03% Topical Ointment (e.g. Protopic 0.03%) Tacrolimus 0.1% Topical Ointment (e.g. Protopic 0.1%)					
Please provide the following information for all NEW requests:					
Diagnosis:					
For the treatment of atopic dermatitis	Othe	r, please sp	ecify:		
Areas affected (check all that apply):					
☐ Face	Flexures				
☐ > 30% of body surface area	ace area				
Information regarding previous topical steroid therapy:					
Topical steroid therapy HAS been utilized → please complete both a) and b)					
a) Name of topical steroid(s) tried, including strength and dosage form:					
b) Response to topical steroid therapy:					
☐ Failure	☐ Requires ongoing use				
☐ Intolerance	Other (please specify):				
☐ Topical steroid therapy has NOT been utilized:					
Contraindication. Please elaborate:					
Other reason(s) topical steroid therapy was NOT tried (please specify):					
Additional information relating to request:					
RENEWAL: This product is eligible for auto-renewal. A Special Authorization renewal request is required only if the Special Authorization approval has lapsed (i.e. the patient has <u>not</u> made a claim for the drug product during the Approval Period).					
	• 4		forward this request to: berta Blue Cross, Clinical Drug Services 0009-108 Street NW, Edmonton, Alberta T5J 3C5 AX: 780-498-8384 in Edmonton • 1-877-828-4106 toll-free all other areas		
ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.					



TACROLIMUS TOPICAL OINTMENT SPECIAL AUTHORIZATION CRITERIA

Patients may or may not meet eligibility requirements as established by Alberta Government sponsored drug programs.

Criteria for Coverage:

TACROLIMUS 0.03 % TOPICAL OINTMENT

"For use in patients 2 to 15 years of age inclusive with atopic dermatitis who are unable to tolerate or have failed topical steroid therapy."

"For use in patients 2 to 15 years of age inclusive with atopic dermatitis who require ongoing use of potent (Class 3 or higher) topical steroids."

"For use in patients 16 years of age and older with atopic dermatitis affecting face and flexures who are unable to tolerate or have failed topical steroid therapy."

"For use in patients 16 years of age and older with atopic dermatitis who require ongoing use of potent (Class 3 or higher) topical steroids over greater than 30 % of body surface area."

"Special authorization for all criteria may be granted for 6 months."

Information is required regarding the patient's diagnosis, previous medications utilized (including specific topical steroids) and the patient's response to therapy. In order to comply with the third criterion, information is also required regarding the area(s) affected. In order to comply with the fourth criterion, information is also required regarding the percentage body surface area affected.

These products are eligible for auto-renewal.

TACROLIMUS 0.1 % TOPICAL OINTMENT

"For use in patients 16 years of age and older with atopic dermatitis affecting face and flexures who are unable to tolerate or have failed topical steroid therapy."

"For use in patients 16 years of age and older with atopic dermatitis who require ongoing use of potent (Class 3 or higher) topical steroids over greater than 30 % of body surface area."

"Special authorization for all criteria may be granted for 6 months."

Information is required regarding the patient's diagnosis, previous medications utilized (including specific topical steroids) and the patient's response to therapy. In order to comply with the first criterion, information is also required regarding the area(s) affected. In order to comply with the second criterion, information is also required regarding the percentage body surface area affected.

These products are eligible for auto-renewal.